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BRCA1 is a well-known DNA repair pathway compo-
nent and a tissue-specific tumor suppressor. How-
ever, its role in hematopoiesis is uncertain. Here, we
report that a cohort of patients heterozygous for
BRCA1 mutations experienced more hematopoietic
toxicity from chemotherapy than those with BRCA2
mutations. To test whether this reflects a require-
ment for BRCA1 in hematopoiesis, we generated
mice with Brca1 mutations in hematopoietic cells.
Mice homozygous for a null Brca1 mutation in
the embryonic hematopoietic system (Vav1-iCre;
Brca1F22–24/F22–24) developed hematopoietic defects
in early adulthood that included reduced hemato-
poietic stemcells (HSCs). Althoughmicehomozygous
for a huBRCA1 knockin allele (Brca1BRCA1/BRCA1) were
normal, mice with a mutant huBRCA1/5382insC allele
and a null allele (Mx1-Cre;Brca1F22–24/5382insC) had se-
vere hematopoietic defects marked by a complete
loss of hematopoietic stem and progenitor cells. Our
data show that Brca1 is necessary for HSC mainte-
nance and normal hematopoiesis and that distinct
mutations lead to different degrees of hematopoietic
dysfunction.INTRODUCTION
Hematopoietic stem cells (HSCs) depend on DNA repair mecha-
nisms to maintain their genomic integrity (Beerman et al., 2014;
Mohrin et al., 2010; Rossi et al., 2007). Deficiencies in DNA repair
proteins impair HSC function, although the nature and severity of
the defects vary among DNA repair pathways. Deficiency for
proteins involved in non-homologous end joining does not affect
HSC frequency or hematopoiesis in normal young adult mice,
but it does reduce HSC function in response to stress (RossiCell
This is an open access article undet al., 2007) and can lead to HSC depletion during aging (Nijnik
et al., 2007). Deficiency for proteins involved in DNA mismatch
repair does not appear to have major effects on hematopoiesis
under normal conditions, but it impairs the capacity of HSCs
to reconstitute irradiated mice (Reese et al., 2003). Deficiency
for homologous recombination-mediated double-strand-break
repair proteins, however, can lead to hematopoietic failure in
patients (Kottemann and Smogorzewska, 2013), and it can
impair hematopoiesis in mice as well as HSC function upon
transplantation into irradiated mice (Bender et al., 2002; Carreau
et al., 1999; Haneline et al., 1999; Ito et al., 2004; Navarro et al.,
2006).
Fanconi anemia is caused by at least 18 different autosomal
recessive mutants in the FA-BRCA repair pathway, including
BRCA2 (Howlett et al., 2002; Xia et al., 2007), PALB2 (Reid
et al., 2007), and BRIP1 (Seal et al., 2006). All three of these pro-
teins physically interact with BRCA1 during DNA repair (Baer and
Ludwig, 2002; Prakash et al., 2015; Xia et al., 2006; Zhang et al.,
2009), raising the question of whether mutations in BRCA1 also
could influence HSC function or hematopoiesis. Two individuals
with developmental defects consistent with Fanconi anemia
were identifiedwith genetic variants in bothBRCA1 alleles (Dom-
chek et al., 2013; Sawyer et al., 2015); however, it is not clear
that these were all deleterious mutations and neither individ-
ual was reported to have hematopoietic defects. If loss-of-func-
tion mutations in BRCA1 impair DNA repair in hematopoietic
cells, this would have broad implications for patients with
BRCA1 mutations, as these patients are at increased risk of
certain cancers that are commonly treated with DNA-damaging
chemotherapies.
Homozygosity for germline loss of function in Brca1 is
embryonic lethal in mice (Drost and Jonkers, 2009). Condi-
tional deletion of Brca1 from breast epithelium in mice leads
to the development of breast cancer, but only when combined
with p53 deficiency (Drost and Jonkers, 2009; McCarthy et al.,
2007). Two recent studies conditionally deleted Brca1 from
hematopoietic cells (Santos et al., 2014; Vasanthakumar
et al., 2016). One showed that leukemia cells transformed
by MLL-AF9 exhibited reduced proliferation and increasedReports 18, 947–960, January 24, 2017 ª 2016 The Author(s). 947
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Characteristics of Human BRCA1 and BRCA2 Mutation
Carriers
Population Parameters BRCA1 BRCA2 Total
Patients (n) total 104 96 200
female 90 87 177
male 14 9 23
Age range 20–79 20–77 –
median 42 46 –
Race (n) black 23 17 40
Asian 8 7 15
Caucasian 33 44 77
hispanic 40 28 68
Cancer (n) total 45 23 68
breasta 33 17 50
ovarian 7 1 8
other 5 5 10
Chemo (n)b total 29 13 42
breast 24 11 35
ovarian 1 1 2
other 4 1 5
aOf the BRCA1 mutation carriers, 25 had ER/PR/HER2 triple-negative
breast cancer (TNBC). None of the 23 BRCA2 mutation carriers had
TNBC.
bThis represents the patients treated at our institution with chemo-
therapy. Most breast cancer patients received four cycles of dose-dense
doxorubicin and cyclophosphamide, followed by four cycles of pacli-
taxel; ovarian or peritoneal cancer patients received four to eight cycles
of carboplatin and paclitaxel (Table S1).differentiation in the absence of Brca1 (Santos et al., 2014).
The second study showed that conditional Brca1 deletion
reduced blood cell counts and colony-forming progenitors.
Transplantation of Brca1-deficient bone marrow cells into irra-
diated mice was associated with lower blood cell counts in
recipient mice and a trend toward lower levels of donor cell
reconstitution 10–15 days after transplantation. However,
this study did not detect a significant reduction in HSC fre-
quency, and the consequences for the long-term reconstitut-
ing capacity of bone marrow cells was not assessed (Vasan-
thakumar et al., 2016). Therefore, it has not yet been tested
whether Brca1 is required for HSC function or whether hetero-
zygosity for BRCA1 mutations affects recovery after chemo-
therapy in humans or in mice.
We evaluated the hematologic effects of chemotherapy on
cancer patients with germline BRCA1 or BRCA2 mutations,
and we found that, in our small cohort, BRCA1 mutations were
associated with an increased risk of hematopoietic toxicity.
Based on these clinical observations, we tested the effects of
BRCA1mutations on hematopoiesis inmice. To do this, we char-
acterized the effects of two different mutant Brca1 alleles on
mouse hematopoiesis. We show that Brca1 is necessary for
HSC maintenance and normal hematopoiesis but that different
alleles exhibit differences in the severity of the HSC phenotype
that do not correlate with differences in the severity of their ef-
fects on embryonic development.948 Cell Reports 18, 947–960, January 24, 2017RESULTS
Association of BRCA1 Mutations with Hematopoietic
Toxicity from Chemotherapy
Patients with germline BRCA1 mutations commonly develop
cancers that are treated with DNA-damaging chemotherapies.
To test whether those patients are at increased risk for hemato-
poietic complications, we analyzed hematopoietic parameters
in patients heterozygous for deleterious mutations in BRCA1
at baseline (healthy patients) and after chemotherapy. We
compared our patients to those who carry deleterious mutations
in BRCA2 for two reasons. First, it allowed for a comparison
cohort that was similar in gender and age (Table 1), and second
because prior data suggested thatBRCA2mutation carriersmay
experience fewer episodes of neutropenia compared to BRCA1
mutation carriers (Shanley et al., 2006). In the latter report, it was
not possible to match for type of chemotherapy regimen and
most of the patients did not receive doxorubicin, a standard
component of current breast cancer treatment. In our cohorts,
most of the patients with BRCA1 or BRCA2 mutations that
received chemotherapy had breast cancer, and they were
treated with four cycles of dose-dense doxorubicin plus cyclo-
phosphamide (both drugs are DNA damaging) followed by four
cycles of paclitaxel.
BRCA1 and BRCA2 mutation carriers at our institution had
normal blood cell counts at steady state (Figures 1A–1F). Both
sets of patients experienced hematopoietic toxicity after chemo-
therapy, though BRCA1 mutation carriers tended to experience
more frequent and severe hematopoietic toxicity from chemo-
therapy than BRCA2 mutation carriers (Figures 1G–1K). This
was evident only in a subset of the patients, as shown by the
wide variations in the post-chemotherapy blood counts (Fig-
ures 1H–1K; blood counts from each patient at the time of
maximum neutrophil toxicity). Severity of maximal toxicity for
blood parameters also was quantified as recommended by the
National Cancer Institute (NCI)’s criteria for adverse events (Fig-
ures 1L–1O; Table 2). Since prophylactic granulocyte-colony
stimulating factor (G-CSF) is standard for patients receiving
dose-dense doxorubicin plus cyclophosphamide and paclitaxel
therapy, the overall rate of febrile neutropenia (neutropenia with
fever) in breast cancer patients at our institution during the last
3 years has averaged 5%. This is consistent with a recently
reported 3.4% overall febrile neutropenia rate for this regimen
in the United States (Caggiano et al., 2005). In contrast, 34%
of BRCA1 mutation carriers experienced febrile neutropenia, a
significantly higher frequency than observed among BRCA2
mutation carriers (0%; p < 0.0001; Figure 1G). The BRCA1 and
BRCA2mutation carriers were relatively young patients (median
age 41.5 and 46, respectively; Table 1), without co-morbidities
and inwhom febrile neutropeniawould not be expected (Kourou-
kis et al., 2008). Consistent with the increased incidence of
febrile neutropenia, we observed a trend toward an increased
incidence of neutropenia among BRCA1 mutation carriers as
compared to BRCA2 mutation carriers (Figure 1I; p < 0.1).
BRCA1 mutation carriers also had a significantly higher fre-
quency of grade 3/4 leukopenia (28% for BRCA1 versus 8%
for BRCA2; Figure 1L; p < 0.05) and grade 3/4 lymphopenia
(31% for BRCA1 versus 0% for BRCA2; Figure 1N; p < 0.05)
Figure 1. Cancer Patients with BRCA1 Mutations Have Increased Hematopoietic Toxicity after Chemotherapy
(A–F) Complete blood cell counts from individuals with BRCA1/2 mutations who had not been exposed to chemotherapy. No significant differences were
observed in (A) white blood cells (WBCs), (B) neutrophils, (C) lymphocytes, (D) monocytes, (E) hemoglobin, or (F) platelets between BRCA1 and BRCA2mutation
carriers (n = 63 BRCA1 and 50 BRCA2 patients). Bars represent means ± SD.
(G) Frequency of febrile neutropenia (FEN) in BRCA1 or BRCA2 cancer patients treated with chemotherapy is shown.
(H–K) Blood count parameters from BRCA1 or BRCA2 patients with the lowest absolute neutrophil counts after treatment with chemotherapy are shown. WBCs
(H), neutrophils (I), lymphocytes (J), and hemoglobin (K) of patients at the time of their neutrophil nadir.
(legend continued on next page)
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Table 2. NCI CTCAE Grading System for Hematologic Toxicity
Lineage Grade 1 Grade 2 Grade 3 Grade 4
Neutrophils <LLN to 1,500/mm3 1,000–1,500/mm3 500–1,000/mm3 <500/mm3
Platelets <LLN to 75,000/mm3 50,000–75,000/mm3 25,000–50,000/mm3 <25,000/mm3
Hemoglobin <LLN to 10 g/dL 8.0–10.0 g/dL <8.0 g/dL life-threatening consequences
Lymphocytes (total) <LLN to 800/mm3 500–800/mm3 200–500/mm3 <200/mm3
Neutropenia, thrombocytopenia, anemia, and lymphopenia were determined from the complete blood count after chemotherapy, and the lowest count
was used for calculating grade of toxicity. All patients with sustained fever of >100.4F in the midst of chemotherapy-induced grade 4 neutropenia
received a first course of IV antibiotics in hospital. Taken fromNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE,
version 3.0). LLN, lower limit of normal.compared to BRCA2 mutation carriers. There was also a trend
toward an increased incidence of grade 3/4 anemia (31% for
BRCA1 versus 0% for BRCA2; Figure 1O) after chemotherapy.
There were no differences in platelet counts between the two co-
horts (data not shown).
There were no correlations of specific BRCA1 mutations
with febrile neutropenia. The small numbers of individuals with
each mutation precluded our ability to determine whether or
not specific mutations in the BRCA1 gene were associated
with toxicity (Table S1). Nevertheless, these data suggest that,
collectively, germline BRCA1 mutations are associated with
a higher-than-expected risk for chemotherapy-associated he-
matopoietic complications.
Brca1 Deficiency in Mice Causes Pancytopenia
The high rate of hematopoietic toxicity in BRCA1 mutation car-
riers after chemotherapy raised the question of whether reduced
BRCA1 function impairs the capacity to regenerate hematopoie-
sis after myeloablation. To test this, we generated Vav1-iCre;
Brca1F22–24/F22–24 mutant mice (Figure S1) (McCarthy et al.,
2007). When the conditional Brca1F22–24 allele is recombined, it
is considered a null allele, as mice that have homozygous dele-
tion of this allele in the germline die before birth, and conditional
deletion in the breast epithelium leads to breast cancer (McCar-
thy et al., 2007). Vav1-iCre deletes in embryonic and adult he-
matopoietic cells, including HSCs (Georgiades et al., 2002).
Vav1-iCre;Brca1F22–24/F22–24 mice at weaning had normal body
weight and appeared healthy. As reported previously (McCarthy
et al., 2007), there was no detectable Brca1 protein in spleen
cells isolated from Vav1-iCre;Brca1F22–24/F22–24 mice (Figure 2A,
top panel). Phosphorylation of H2AX was increased in Vav1-
iCre;Brca1F22–24/F22–24 splenocytes, as would be expected for
a functionally null DNA repair gene (Figure 2A, bottom panel).
Vav1-iCre;Brca1F22–24/F22–24 mice developed severe pancyto-
penia. The 3- to 6-week-old Vav1-iCre;Brca1F22–24/F22–24 mice
had significantly decreased absolute numbers of white blood
cells, including neutrophils and lymphocytes, as well as signifi-
cantly reduced numbers of platelets compared to controls (Fig-
ures 2B–2G). Deletion of a single allele of Brca1 was sufficient to(L–O) Frequency and severity of hematopoietic toxicity inBRCA1 orBRCA2 cance
bar,BRCA2mutation carriers). Percentages of patients affected with any grade an
(O) anemia are shown. Grades of blood cell count toxicity were assigned as sta
Adverse Events v3.0 (Trotti et al., 2003). Neutropenic fever was defined as an a
(100.4F). Statistical significance in (A)–(F) and (H)–(K) was assessed using a two-t
950 Cell Reports 18, 947–960, January 24, 2017slightly but significantly reduce white blood cell (WBC) and
lymphocyte levels (Figures 2B and 2D).
Vav1-iCre;Brca1F22–24/F22–24 mice had a shortened lifespan
and most died spontaneously without appearing ill, likely as a
result of hematopoietic failure and its consequences (acute infec-
tion, bleeding, etc.). Half of the Vav1-iCre;Brca1F22–24/F22–24mice
died by 75 days (Figure 2H). A fraction (27%, 7/26) of the Vav1-
iCre;Brca1F22–24/F22–24 mice that survived beyond 3 months of
age did become moribund (hunched, immobile, and cold) prior
to death, and they developed lymphocyte-infiltrated splenomeg-
aly (Figure S2A). Unlike the prior report that found p53 mutations
in some spleens that were Brca1 null (Vasanthakumar et al.,
2016), when we used RNA sequencing (RNA-seq) to analyze for
mutations in expressed genes, only wild-type p53 was found
in these enlarged spleens. However, consistent with the same
report, T cell infiltration was present based on a decreased B
cell-specific gene expression and an increased T cell gene
expression pattern in the enlarged spleens (Figure S2B). These
data suggest that deletion of Brca1 from mouse hematopoietic
cells has thepotential to promote thedevelopment of hematopoi-
etic malignancies from surviving progenitors (Vasanthakumar
et al., 2016).
Brca1 Deficiency Causes HSC Depletion
To identify the cause of the pancytopenia in Vav1-iCre;
Brca1F22–24/F22–24 mice, we examined hematopoiesis in their
bone marrow. The 6-week-old Vav1-iCre;Brca1F22–24/F22–24
mice had a significant reduction in bone marrow cellularity
compared to littermate controls (Figure 3A; p < 0.05). Strikingly,
the bone marrow of Vav1-iCre;Brca1F22–24/F22–24 mice had only
3% of the CD150+CD48LineageSca-1+ckit+ (CD150+CD48
LSK) (Kiel et al., 2005) HSCs observed in controls (Figures 3B
and 3C). This decline in HSC frequency did not reflect HSCmobi-
lization, as HSC frequency was not increased in the spleens of
Vav1-iCre;Brca1F22–24/F22–24 mice (Figure 3D). Although there
was a trend toward reducedHSC frequency in the heterozygotes
(Vav1-iCre;Brca1F22–24/+), the difference was not statistically sig-
nificant. There was also a severe reduction in the frequency and
absolute number of hematopoietic progenitor cells in the boner patients treatedwith chemotherapy (black bar,BRCA1mutation carriers; gray
d severe grade 3 or grade 4 (L) leukopenia, (M) neutropenia, (N) lymphopenia, or
ndardized by the National Cancer Institute Common Terminology Criteria for
bsolute neutrophil count (ANC) < 500 cells/mm3 and a sustained fever >38C
ailed Student’s t test and in (G) and (L)–(O) using a Fisher’s exact test (*p < 0.05).
Figure 2. Brca1 Deficiency Leads to Severe
Hematologic Abnormalities
(A) Western blot analysis is shown for mouse
Brca1, Hip1 (loading control), and gH2AX in spleen
extracts (100 mg per lane) from Vav1-iCre;
Brca1F22–24/F22–24 (D/D; n = 4) and control (+/+;
n = 4) mice.
(B–G) Blood counts from 3- to 6-week-old wild-
type control mice (+/+; n = 18), Vav1-iCre;
Brca1F22–24/+ (D/+; n = 24), and Vav1-iCre;
Brca1F22–24/F22–24 (D/D; n = 20) mice. (B) WBCs,
(C) neutrophils, (D) lymphocytes, (E) monocytes,
(F) hemoglobin, and (G) platelets are shown.
(H) Kaplan-Meier survival curve of control (black
line; +/+; n = 14) and Vav1-iCre;Brca1F22–24/F22–24
(red line; D/D; n = 14) mice. All data represent
means ± SD. Statistical significance was as-
sessed using a two-tailed Student’s t test except
in (H) where a log-rank test was used (*p < 0.05,
**p < 0.01, and ***p < 0.001).marrow, including CD150CD48LSK multipotent progenitors
(MPPs) (Oguro et al., 2013), CD34+CD16/32lowCD127
Sca-1LK common myeloid progenitors (CMPs), CD34+CD16/
32highCD127Sca-1LK granulocyte macrophage progenitors
(GMPs), CD34CD16/32lowCD127Sca-1LK megakaryocyte
erythroid progenitors (MEPs) (Akashi et al., 2000) (Figures
3E–3H and S3B–S3E), B220+IgM B cell progenitors,
B220+IgM+ B cells (Figures 3I and S3F), and CD3+ T cells (Fig-
ures 3J and S3G) in Vav1-iCre;Brca1F22–24/F22–24 bone marrow
compared to controls. The frequency and absolute number ofCell RCD11b+Gr1+ myeloid cells (GM) were
not significantly reduced in Vav1-iCre;
Brca1F22–24/F22–24 bone marrow (Fig-
ures 3K and S3H). The frequency of
CD71+Ter119+ erythroid progenitors
was significantly increased in Vav1-
iCre;Brca1F22–24/F22–24 bonemarrow (Fig-
ure 3L), but the absolute number was
unchanged (Figure S3I). These data
indicate that Brca1 deficiency in Vav1-
iCre;Brca1F22–24/F22–24 mice depletes
HSCs and hematopoietic progenitor cells
in young adult mice.
Competitive bone marrow trans-
plantation assays were performed to
functionally analyze HSCs from Vav1-
iCre;Brca1F22–24/F22–24 mice (n = 3 do-
nors into five recipients each). Bone
marrow cells from 6-week-old Vav1-
iCre;Brca1F22–24/F22–24 (CD45.2+) mice
and Brca1F22–24/F22–24 (CD45.2+) con-
trols were each transplanted with equal
numbers of wild-type congenic bone
marrow cells (CD45.1+) into lethally irra-
diated mice (CD45.1+). Four weeks after
transplantation, few donor-derived
Vav1-iCre;Brca1F22–24/F22–24 (CD45.2+)cells were detected in the peripheral blood of recipient
mice (Figure S3J). By 8 weeks after transplantation, there
were no donor-derived B, T, or myeloid cells in the pe-
ripheral blood of these recipients, some of which were
followed out to 20 weeks without any detectable donor
cell reconstitution (Figures S3K–S3M). Consistent with the
decline in the frequency of HSCs based on surface marker
phenotype (Figure 3B), Vav1-iCre;Brca1F22–24/F22–24 mice
had no functional HSCs capable of reconstituting irradiated
mice.eports 18, 947–960, January 24, 2017 951
Figure 3. Brca1 Deficiency Causes HSC Depletion
(A) Bonemarrow (BM) cellularity (1 femur and 1 tibia) of control (+/+; n = 4), Vav1-iCre;Brca1F22–24/+ (D/+; n = 5), and Vav1-iCre;Brca1F22–24/F22–24 mice (D/D; n = 4)
is shown.
(B) Frequency (number of HSCs/total BM cells) of HSCs is shown in the BMof control (+/+; n = 7; white bar), Vav1-iCre;Brca1F22–24/+(D/+; n = 5; light gray bar), and
Vav1-iCre;Brca1F22–24/F22–24 mice (D/D; n = 4; dark gray bar).
(C) Representative flow cytometry plot shows CD150+CD48LSK HSCs in wild-type mice (+/+; top panel) and Vav1-iCre;Brca1F22–24/F22–24 mice (D/D; bottom
panel).
(legend continued on next page)
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Heterozygosity for Brca1 Reduces HSC Reconstituting
Capacity
To begin to determine if the bone marrow of Vav1-iCre;
Brca1F22–24/+ mice has increased sensitivity to DNA stress, we
treated a cohort of Vav1-iCre;Brca1F22–24/+ mice with two cycles
of cyclophosphamide, and we monitored their blood counts for
recovery abnormalities. Under these specific conditions, we
did not observe consistent differences between heterozygous
and wild-type mice (Figures S3R–S3W). To observe more subtle
differences, it may be necessary to either give different doses of
cyclophosphamide, treat with several more drug cycles, or treat
with other drugs used in our patients, such as cisplatin, doxoru-
bicin, and paclitaxel.
We also have tested heterozygous bone marrow sensitivity
to proliferative DNA stress by evaluating whether haploinsuffi-
ciency for Brca1 influences the bone marrow-reconstituting ca-
pacity of HSCs. To do this, bone marrow cells from 6-week-old
Vav1-iCre;Brca1F22–24/+ (CD45.2+) mice and Brca1+/+ (CD45.2+)
controls were each transplanted with equal numbers of wild-
type congenic bone marrow cells (CD45.1+) into lethally irradi-
ated mice (CD45.1+). We observed no significant differences
between Vav1-iCre;Brca1F22–24/+ and control cells in the recon-
stitution of primary recipient mice (Figures S3J–S3M). These re-
sults from challenges with chemotherapy and transplantation
suggest that haploinsufficiency of Brca1 in mice does not exhibit
exceptionally high bone marrow sensitivity.
To further test if heterozygosity impaired HSC self-renewal
potential, we serially transplanted bone marrow cells from the
primary recipient mice into secondary recipient mice; 16 weeks
after primary transplantation, we transplanted bonemarrow cells
from primary recipient mice with levels of donor cell reconstitu-
tion (CD45.2+) nearest the median values in each treatment.
Vav1-iCre;Brca1F22–24/+ cells gave significantly lower levels of
donor cell reconstitution in all lineages compared to Brca1+/+
control cells in secondary recipients (Figures S3N–S3Q). These
results suggest that Vav1-iCre;Brca1F22–24/+ HSCs do in fact
exhibit a reduced self-renewal capacity as compared to wild-
type HSCs. Although single Vav1-iCre transgenic mice were
not used as controls in this cohort, complete blood count
(CBC) abnormalities or defects in primary or secondary reconsti-
tution by bone marrow cells from Vav1-iCre mice in the same
pure C57BL/6 background have not been observed previously
(Foley et al., 2013). These observations in mice are consistent
with greater chemotoxicity in humans with BRCA1 mutations,
and they suggest that heterozygosity for a loss-of-function mu-
tation inBrca1 can impair the ability to regenerate hematopoiesis
after one or more cycles of chemotherapy (Figure 1G).
Because serial bone marrow transplantation was required to
observe a deleterious effect of proliferative stress on Brca1 hap-
loinsufficient HSCs, it remains possible that the heterozygous
genotype does not impose as much chemotherapeutic toxicity
as our human data would suggest. Since our patient data are
from a retrospective analysis of a small cohort (Figure 1G),(D) Frequency of HSCs is shown in the spleen of control (n = 3), Vav1-iCre;Brca1
(E–L) Frequency of (E) MPPs, (F) CMPs, (G) GMPs, (H) MEPs, (I) B lineage cells, (J
control (+/+; n = 7; white bar), Vav1-iCre;Brca1F22–24/+(D/+; n = 5; light gray bar)
significance was assessed using a two-tailed Student’s t test (*p < 0.05, **p < 0.further work to prospectively observe more humans with in-
herited cancer predisposition mutations who are treated with
chemotherapy is necessary. Also, generation and serial treat-
ment of more Brca1 haploinsufficient mice with various bone
marrow stresses that include repeated cycles of cyclophos-
phamide, doxorubicin, cisplatin, and paclitaxel will need to be
completed.
Generation of Wild-Type and Mutant Knockin Alleles
of Human BRCA1
We and others have found that frameshift or stop-gain mutations
in the last few exons of the BRCA1 gene encode non-functional
mutant proteins (Scully et al., 1999) expressed from messages
that do not experience RNA decay (Perrin-Vidoz et al., 2002;
Soyombo et al., 2013). These C-terminal mutations frequently
lead to cancer phenotypes distinct from those caused by muta-
tions elsewhere in the gene (Rebbeck et al., 2015). We have
found that the common Ashkenazi Jewish BRCA1 5382insC
founder mutation results in expression of a mutant transcript in
the same amounts as BRCA1 wild-type message in fibroblasts,
induced pluripotent stem cells, and teratomas (Soyombo et al.,
2013). The 5382insC mutation leads to a C-terminal frameshift
mutation. We wondered whether this hypomorphic allele would
have a less severe hematopoietic phenotype as compared to
the null mutation.
To assess the 5382insC mutation’s effects on embryogen-
esis and hematopoiesis and to ensure that any abnormalities
observed with humanization of the Brca1 locus with the
BRCA1 5382insC allele were due to the abnormal BRCA1, we
generated mice that were humanized with wild-type human
BRCA1 in place of mouse Brca1. To do this, we designed a
targeting vector that allowed for expression of both a wild-
type BRCA1 allele and, upon Cre-mediated recombination, the
BRCA1 5382insC mutation (Figures 4A and S4A). C57BL/6 em-
bryonic stem cells (ESCs) were electroporated with the targeting
construct and screened for correctly targeted knockin alleles
(Figure S4B). Two lines that were correctly targeted and ex-
pressed human BRCA1 (Figure S4C, lanes 3–6) also were elec-
troporated with CMV-Cre to generate ESC lines that expressed
the recombined Brca15382insC mutant allele (Figure S4C, lanes
7 and 8). The Brca1BRCA1 allele substituted for wild-type mouse
Brca1 function, as evidenced by the fact that fully humanized
homozygotes (Brca1BRCA1/BRCA1) were born at Mendelian fre-
quencies (Figure 4B, left), and they remained alive and well
with no hematopoietic abnormalities (Figures 4D–4P) for up to
1.5 years of age (Figure S4D).
To generate mice with the BRCA1 5382inC allele
(Brca15382insC) in the germline, Brca1BRCA1/BRCA1 mice were
mated with CMV-Cre deletor mice (Dupe´ et al., 1997). The prog-
eny with recombination in the germline were then used for further
analysis of mice who carried this human mutation. In contrast to
the Brca1BRCA1 allele, homozygosity for the Brca15382insC allele
was embryonic lethal, as 208 progeny from the heterozygousF22–24/+ (n = 3), and Vav1-iCre;Brca1F22–24/F22–24 mice (n = 3).
) T lineage cells, (K) myeloid cells, and (L) erythroid cells in the bone marrow of
, and Vav1-iCre;Brca1F22–24/F22–24 mice (D/D; n = 4; dark gray bar). Statistical
01, and ***p < 0.001).
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Brca15382insC/+ parents included no Brca15382insC/5382insC homo-
zygotes and an expected frequency of heterozygotes and wild-
type mice (Figure 4B, right; p < 0.0001). This lethality confirms
that the 5382insC allele encodes a severe loss-of-function muta-
tion. These data thus indicate that the wild-type human BRCA1
cDNA rescues mouse embryonic lethality (suggesting that alter-
native splicing is not necessary for this gene to function properly
in mice) and that the BRCA1 5382insC mutant does not.
Hematopoiesis in Mice with the Brca15382insC Mutation
To assess the effects of the germline Brca15382insC mutant
allele on hematopoiesis, we crossed the Brca15382insC/+ mice
with the Vav1-iCre;Brca1F22–24/+ mice to generate Vav1-iCre;
Brca1F22–24/5382insC biallelic mutant mice. This is a similar genetic
configuration predicted to occur in many human cancers—a
germline mutation (Brca15382insC) in one allele followed by so-
matic loss of heterozygosity as a result of deletion of the second
allele. The biallelic Vav1-iCre;Brca1F22–24/5382insC mice were
healthy at weaning. In contrast to the severe hematopoietic de-
fects in Vav1-iCre;Brca1F22–24/F22–24 mice, average peripheral
blood counts (Figures S5A–S5F) and bone marrow stem and
progenitor cell frequencies were normal in adult Vav1-iCre;
Brca1F22–24/5382insC mice (Figures S5H–S5P). However, the
normal blood counts may be attributed to the main presence
of cells that lacked recombination of the floxed null allele
(Figure S5G). In contrast to the presence of only non-recombined
hematopoietic cells in Vav1-iCre;Brca1F22–24/5382insC mice (same
amplification curve as obtained from DNA derived from Cre-
negative Brca1F22–24/+ control bone marrow), hematopoietic
cells from Vav1-iCre;Brca1F22–24/F22–24mice exhibited significant
recombination (Figure S5G). A possible explanation for the lack
of somatic recombination of the Brca1F22–24 allele when the
germline allele was Brca15382insC is that the BRCA15382insC pro-
tein is more deleterious to hematopoietic cells than the simple
null allele, and, thus, the only cells that survived into adulthood
were those that were not somatically recombined.
To test this, we used Mx1-Cre to conditionally recombine the
floxed allele in the adult hematopoietic system. The un-induced
Mx1-Cre;Brca1F22–24/F22–24 biallelic mice were healthy at wean-
ing, but, when Mx1-Cre was induced with pIpC at 4 weeks of
age, these mice experienced fully penetrant rapid morbidity
and mortality. In contrast, Mx1-Cre;Brca1F22–24/F22–24 mice
did not (Figure 5A). To confirm there were no differences in
recombination, we generated mice with the null mutation in
the germline. To do this, Brca1F22–24/F22–24 mice were mated
with CMV deletor mice (Dupe´ et al., 1997). The progeny with
recombination in the germline (Brca1D/+) were then used toFigure 4. Humanization of the Brca1 Allele with Wild-Type BRCA1 or B
(A) Targeting vector used to knock BRCA1 into theBrca1 locus. This allowed for h
point mutation.
(B) BRCA1 5382insC knockin is embryonic lethal. (Left) Number of offspring and
shown. (Right) Number of offspring and the genotypes produced from 30 hetero
(C–G) Blood counts from wild-type control mice (+/+; n = 11), homozygous Brc
(BRCA1/+; n = 7). (C) WBCs, (D) neutrophils, (E) platelets, (F) lymphocytes, and (
(H–P) Frequency of (H) HSCs, (I) MPPs, (J) CMPs, (K) GMPs, (L) MEPs, (M) B linea
marrow of control (+/+; n = 3; white bar) and Brca1huBRCA1/huBRCA1 (BRCA1/BRCA
Student’s t test. There were no significant differences between the genotypes.generate Mx1-Cre;Brca1F22–24/D biallelic mice to compare to
Mx1-Cre;Brca1F22–24/5382insC biallelic mutant mice. Again, the
Mx1-Cre;Brca1F22–24/D biallelic mice survived while the Mx1-
Cre;Brca1F22–24/5382insC biallelic mutant mice did not (Figure 5A).
These data indicate that the Brca1D/5382insC genotype is more
deleterious to hematopoietic cells than the Brca1D/D genotype.
The rapidmortality inpIpC-treatedMx1-Cre;Brca1F22–24/5382insC
mice was associated with severe pancytopenia. The organs
of the pIpC-induced Mx1-Cre;Brca1F22–24/5382insC mice were
pale (data not shown). As expected, for both the Mx1-Cre;
Brca1F22–24/F22–24 and Mx1-Cre;Brca1F22–24/5382insC mutant mice
in Figure 5A, therewere significantly decreased absolute numbers
of white blood cells, including neutrophils and lymphocytes, as
well as significantly reduced numbers of platelets (Figures 5B–
5F). However, Mx1-Cre;Brca1F22–24/5382insC mice had a signifi-
cantly more severe pancytopenia than Mx1-Cre;Brca1F22–24/D
mice with the lowest absolute numbers of white blood cells,
including neutrophils, monocytes, and lymphocytes, as well as
reduced numbers of platelets and hemoglobin (Figures 5B–5G).
The severe anemia in the Mx1-Cre;Brca1F22–24/5382insC mice
was the largest and most significant difference from the Mx1-
Cre;Brca1F22–24/D mice (Figure 5G). Since the half-life of mouse
red blood cells in wild-type mice has been measured at more
than 20 days (Van Putten, 1958), it is possible there was bleeding
secondary to the severe thrombocytopenia. In fact, in two mice
that were necropsied immediately after death, we observed
large pools of blood in the abdominal and thoracic cavities.
Thrombocytopenia can occur quickly with the loss of pro-
genitors, as mouse platelet half-life has been estimated to be
3.4 days (Jayachandran et al., 2010).
To further characterize pIpC-induced Mx1-Cre;
Brca1F22–24/5382insC mice, we examined hematopoiesis in their
bone marrow. The 6-week-old Mx1-Cre;Brca1F22–24/5382insC
mice that had been treated with pIpC at 4 weeks of age
had a severe reduction in HSCs and early progenitors
compared to pIpC-treated controls (Figures 5H–5L; p <
0.01). In fact, the bone marrow of pIpC-treated Mx1-Cre;
Brca1F22–24/5382insC mice had no detectable HSCs (Figure 5H).
Hematopoietic progenitors, including MPPs, CMPs, GMPs,
and MEPs, also were not detectable in the bone marrow of
Mx1-Cre;Brca1F22–24/5382insC mice (Figures 5I–5L). When
compared with hematopoiesis in Mx1-Cre;Brca1F22–24/F22–24
mice (Vasanthakumar et al., 2016) (data not shown), a more
severe hematopoietic defect in Mx1-Cre;Brca1F22–24/5382insC
mice is present, suggesting that the BRCA15382insC protein is
more deleterious to hematopoietic stem and progenitor cells
than the null allele.RCA1 5382insC Knocked-In cDNA Sequences
umanization of the Brca1 gene with a wild-type BRCA1 or the BRCA1 5382insC
the genotypes produced from 15 heterozygous Brca1BRCA1/+ mating pairs are
zygous Brca15382insC/+ (InsC) mating pairs are shown.
a1huBRCA1/huBRCA1 (BRCA1/BRCA1; n = 5), and heterozygous Brca1huBRCA1/+
G) monocytes are shown.
ge cells, (N) T lineage cells, (O) myeloid cells, and (P) erythroid cells in the bone
1; n = 3; light gray bar). Statistical significance was assessed using a two-tailed
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DISCUSSION
In this article, we show a cohort of patients with BRCA1 muta-
tions that experienced increased hematopoietic toxicity and
complications after cancer chemotherapy. We also observed
that Brca1 is required for HSC function and normal hemato-
poiesis in mice. When Brca1 was conditionally deleted from
embryonic hematopoietic cells, young adult mice developed
pancytopenia (Figure 2) and a loss of nearly all HSCs (Figure 3).
Moreover, heterozygosity for a loss-of-function allele of Brca1
in mouse hematopoietic cells led to a slight but significant
decrease in white blood cells and lymphocytes (Figure 2), as
well as deficits in HSC reconstituting potential upon serial trans-
plantation (Figure S3).
These results are consistent with a reduced hematopoietic
regenerative capacity in BRCA1 heterozygous humans after
chemotherapy, suggesting that even a partial loss of BRCA1
function reduces the capacity for hematopoietic recovery due
to direct DNA damage or replication stress after myeloablation.
The concept that replication stress leads to more chemothera-
peutic toxicity for BRCA1 mutation carriers is also consistent
with prior work that has suggested there is enhanced replication
stress (due to decreased stalled fork repair) in BRCA1 heterozy-
gous epithelial cells. This abnormality in heterozygous cells was
hypothesized to enhance the formation of tumors in epithelial
cells (Pathania et al., 2014).
These data suggest a cell death or transformation tissue
specificity hypothesis, and they could explain why patients
with germline BRCA1mutations have a predisposition to epithe-
lial cancers but do not have a predisposition to hematological
malignancies. The ultimate loss of BRCA1 heterozygosity, which
is promoted by diminished DNA repair in the heterozygous state
and is thought to be required for the transformation of epithelial
cells to cancer (Pathania et al., 2014), is not tolerated by hemato-
poietic stem cells.
This is the first report of generation and characterization of a
humanized Brca1 allele. The human BRCA1 cDNA was knocked
into themouseBrca1 locus to study its function. Humanization of
mouse genes has proven useful for in vivo functional evaluation
of human p53 mutations (Song et al., 2007). Like p53, the intro-
duction of human mutations into the mouse Brca1 allele is
advantageous, as there are significant differences in amino
acid sequence between mouse Brca1 and human BRCA1. The
mouse protein is only 60% identical to the human BRCA1 protein
(Sharan et al., 1995). Our finding of embryonic lethality for the
Brca15382insC/5382insC genotype, but not in un-recombined
Brca1BRCA1/BRCA1 mice (Figure 4), confirms that human BRCA1Figure 5. Substitution of Mouse Brca1 with the Human BRCA1 538
Hematopoietic Phenotype than Homozygous Brca1-Null Mice
(A) Kaplan-Meier survival curve of control (black line; Brca1+/+; n = 4),Mx1-Cre;B
Brca1D/D), and Mx1-Cre;Brca1F22–24/5382insC (red line; Brca1D/insC; n = 7) mice is s
(B–G) Complete blood cell counts from wild-type mice (Brca1+/+; n = 4), Mx1
(Brca1D/D), and Mx1-Cre;Brca1F22–24/5382insC (Brca1D/insC; n = 7 mice). (B) WBCs
globin are shown. All data represent means ± SD.
(H–P) Frequency of (H) HSCs, (I) MPPs, (J) CMPs, (K) GMPs, (L) MEPs, (M) B linea
marrow of control (+/+; n = 3; white bar) andMx1-Cre;Brca1F22–24/5382insC (D/+; n
Student’s t test except in (A) where a log-rank test was used (*p < 0.05, **p < 0.0can perform many of the necessary functions of mouse Brca1
after being knocked into the mouse Brca1 locus.
Conditional deficiency for Brca1 using Mx1-Cre in adult
mice previously has been reported to increase differentiation in
MLL-AF9-induced leukemia (Santos et al., 2014), diminish he-
matopoietic cell proliferation in vitro, and lead to mild leukopenia
and anemia (Vasanthakumar et al., 2016). However, neither of
these studies reported a deleterious effect of Brca1 deficiency
on HSC frequency or function. Use of the Vav1-iCre allele to
delete Brca1 in embryonic and adult HSCs and use of the new
human Brca15382insC allele were not part of the prior studies.
The use of different Cre alleles suggests that deletion of Brca1
in the embryonic HSCs (Vav1-iCre) may be more deleterious
than deletion in adult HSCs (Mx1-Cre).
A trivial explanation for why an HSC defect was only observed
in mice using the Vav1-iCre allele for conditional deletion of
Brca1 is that there was more recombination in HSCs with the
Vav1-iCre allele compared to those with the Mx1-Cre allele.
Although this explanation is not possible to confirm or refute
without analysis of the original mice, because Vasanthakumar
et al. (2016) did provide evidence for full recombination in
hematopoietic cells from their Mx1-Cre transgenic mice, it is
an unlikely explanation.
Different BRCA1 mutations have been shown to have distinct
effects on cancer phenotypes. Humans with mutations at the
extreme C and N termini of BRCA1 experience more breast
cancer and less ovarian cancer compared to humans with muta-
tions in themiddle of theBRCA1 gene (Rebbeck et al., 2015). Our
surprising observation that the Brca15382insC mutation led to a
more severe adult hematopoietic phenotype than the Brca1-
null mutation (Figure 5) suggests that distinct germline BRCA1
mutations may result in different degrees of chemotherapeutic
toxicity as well. More patients with these mutations are needed
to make associations, and more investigation into the mecha-
nism of this increased toxicity of the Brca15382insC allele in the
mice will be important.
Because the Brca15382insC allele, in contrast to the null allele,
expresses a mutant protein (Figure S4C versus Figure 2A), it
could indeed have hypo- or hypermorphic effects on cells.
Expression of the BRCA1 5382insC mutant mRNA from humans
heterozygous for the BRCA1 5382insC mutation is equivalent
to the expression of the wild-type mRNA from the other allele
in primary human fibroblasts, induced pluripotent stem cells,
and teratomas. However, the expression of BRCA1 5382insC
in these cells does not promote excessive cell death, differenti-
ation, survival, or growth (Soyombo et al., 2013). Further, heter-
ologous expression of this mutant BRCA1 in cell lines does not2insC Generates a Compound Heterozygote with a More Severe
rca1F22–24/F22–24 (n = 7) plusMx1-Cre;Brca1F22–24/D (n = 5) (green dashed line;
hown.
-Cre;Brca1F22–24/F22–24 (n = 4 mice) plus Mx1-Cre;Brca1F22–24/D (n = 5) mice
, (C) neutrophils, (D) lymphocytes, (E) monocytes, (F) platelets, and (G) hemo-
ge cells, (N) T lineage cells, (O) myeloid cells, and (P) erythroid cells in the bone
= 3; light shaded bar). Statistical significance was assessed using a two-tailed
1, and ***p < 0.001).
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lead to altered growth or survival (data not shown). These ob-
servations may be due to the expression from the normal
BRCA1 allele. The mutant protein may only be detrimental in a
completely deficient BRCA1 background. Further studies to
understand why the BRCA1 5382insC allele leads to an in vivo
phenotype distinct from the Brca1-null allele are necessary.
Stemcells are susceptible toDNAdamagedue to their longevity
and self-renewal potential. HSCs frommicewithmutations inDNA
damage repair proteins that also lead to cancer susceptibility syn-
dromes, such as Brca2 (Navarro et al., 2006) and Msh2 (Reese
et al., 2003), have defects in their ability to reconstitute bone
marrow in irradiated mice, and mice with mutant Rad50 exhibit
hematopoietic failure (Bender et al., 2002). However, the hemato-
poietic phenotypewe observed afterBrca1 deletion ismuchmore
severe than the phenotypes reported in these studies.
Several mouse models have been generated to study BRCA1-
mutant breast cancer (Dine and Deng, 2013; Drost et al., 2011;
Drost and Jonkers, 2009; Evers and Jonkers, 2006; Shakya
et al., 2011). Thesemodels confirm that Brca1maintains genome
stability in vivo and that, without normal Brca1 in breast epithelial
tissues, breast tumorigenesis occurs. However, breast cancer
develops in Brca1-knockout mice only after a long latency
(even if p53 is also deficient). This is consistent with the fact
that human BRCA1 mutation carriers are only diagnosed with
cancer as adults, if ever.
Here we describe mice with different Brca1 alleles mutated
specifically in the hematopoietic system that have distinct phe-
notypes, which, in contrast to the breast cancer phenotype,
occur rapidly and are fully penetrant (for allele/phenotype sum-
mary, see Table S2). In addition to the new information about
the role of Brca1 in hematopoiesis, these allele combinations
provide the field with powerful tools for rapid investigation of
the pathogenicity of BRCA1 variants of unknown significance.
Finally, given the potent requirement for Brca1 in HSCs, an
inherited BRCA1 mutation may be a marker to add to the list of
patient risk factors, such as age and co-morbidities (Caggiano
et al., 2005), that support the prophylactic use of growth factors
and antibiotics and close monitoring for chemotherapy-related
hematopoietic complications. Preventative use ofmyeloid growth
factor support may, however, be counterproductive if unrepaired
replication-induced mutations are increased in BRCA1 heterozy-
gotes. Prophylactic growth factor support and antibiotics should,
therefore, be evaluated prospectively in BRCA1mutation carriers
who are receiving chemotherapy.
EXPERIMENTAL PROCEDURES
Patients
A list of patients withBRCA1 orBRCA2mutations, treated between January 1,
2011, andOctober 31, 2014, was identified from the University of Texas South-
western Medical Center’s Cancer Genetics database. Patients were catego-
rized based on cancer type and chemotherapy treatments. A retrospective
chart review was then conducted on these patients to collect information on
patient characteristics (Table 1), as well as co-morbidities and past medical/
surgical histories, type of cancer, age of diagnosis, treatment, treatment com-
plications (if applicable), and complete blood cell counts. For any patient who
had at least one complete blood cell count recorded in their medical record,
baseline completebloodcell count valueswere selected for eachpatient based
on the following criteria: pre-treatment (but as close to beginning of therapy as
possible within 5 years of cancer diagnosis), no active infection, no procedural958 Cell Reports 18, 947–960, January 24, 2017context (e.g., post-biopsyor post-operative), anddidnot appear tobeanoutlier
if other complete blood cell counts were available for comparison.
For the patients who underwent chemotherapy for their cancer, the most
severe adverse hematopoietic event during chemotherapy and its associated
toxicity score were recorded. Grades of blood cell count toxicity were as-
signed based on the National Cancer Institute Common Terminology Criteria
for Adverse Events v3.0 guidelines (Trotti et al., 2003) (Table 2). Neutropenic
fever was defined as an absolute neutrophil count <500 cells/mm3 and fever.
Fever was defined as a single oral temperature of >38.3C (101F) or a temper-
ature of >38.0C (100.4F) sustained for more than 1 hr.
Following collection of these data, statistical analyses were conducted on
de-identified data. Range, mean, and SDs of complete blood cell components
(neutrophils, platelets, hemoglobin, etc.) in BRCA1/2 mutation carriers were
compared to the normal ranges. Analyses of variations in complete blood
cell components in response to different chemotherapy regimens also were
evaluated for differences between the BRCA1 and BRCA2 mutant patients.
This study (STU 072014-043; Analysis of Complete Blood Counts in BRCA
Mutation Carriers) was approved by the University of Texas Southwestern
Medical Center Institutional Review Board.
Mice
The Brca1F22–24 (McCarthy et al., 2007), Mx1-Cre (Rajewsky et al., 1996),
and Vav1-iCre (Georgiades et al., 2002) alleles, all on a C57BL/6 pure back-
ground, have been described previously, and they were obtained from Jack-
son Laboratories. C57BL/Ka-Thy-1.2 (CD45.1) mice were used as transplant
recipients. Both male and female mice between 6 and 14 weeks old were
used in all studies. Mx1-Cre was induced as describe previously (Oravecz-Wil-
son et al., 2009).
TheBRCA1 knockinmiceweregeneratedasdescribed in detail in the Supple-
mental Experimental Procedures and Figure S4. Briefly, the targeting vectorwas
constructed to generate a knockin allele that conditionally generated theBRCA1
5382insCmutation aswell as constitutively humanizedBRCA1mice (Figures 4A
and S4). These strains are available through the Jackson Laboratory Repository
(JAX Stock No. 030081, Humanized BRCA1 KI -or- [Brca1huBKI/huBKI] and JAX
Stock No. 030082, Humanized BRCA1 5382insC KI -or- [Brca15382insC]).
All Brca1-mutant mice were genotyped from tail snips using real-time PCR
assays designed by and available from Transnetyx. The assays were designed
to detect the wild-type and mutant alleles in the presence or absence of
recombination. Mice were housed in the Unit for Laboratory Animal Medicine
at the University of Texas Southwestern Medical Center under specific path-
ogen-free conditions, and they were monitored regularly for evidence of dis-
ease and abnormal peripheral blood cell counts. The animal use protocol
was approved by the University of Texas Southwestern Institutional Animal
Care and Use Committee (APN 2011-0143).
Bone Marrow Transplantation
Adult recipient mice (CD45.1) were administered a minimum lethal dose of
radiation using an XRAD 320 X-ray irradiator (Precision X-Ray) to deliver
two doses of 540 rad (1,080 rad in total) at least 3 hr apart. Cells were
injected into the retro-orbital venous sinus of anesthetized recipients.
For competitive bone marrow transplants, 5 3 105 donor and 5 3 105 recip-
ient cells were transplanted. Blood was obtained from the submandibular
plexus of recipient mice at the indicated time points after transplantation.
Red blood cells were lysed with ammonium chloride potassium buffer.
The remaining cells were stained with antibodies (Tonbo Biosciences)
against CD45.2, CD45.1, CD45R (B220), CD11b, CD3, and Gr-1 to assess
donor cell engraftment. Mice that died were omitted from the analyses.
Hematopoietic Analysis
Bonemarrow cells were isolated by flushing the long bones (femurs and tibias)
in Ca2+- and Mg2+-free Hank’s buffered salt solution (Corning Life Sciences)
supplemented with 3% heat-inactivated bovine serum (Gibco). Spleens
were prepared by crushing tissues between frosted slides. Cell number and
viability were assessed by a Vi-CELL cell viability analyzer (Beckman Coulter)
or by counting on a hemocytometer.
Flow cytometric analysis of specific hematopoietic progenitors was per-
formedaspreviously described (Foley et al., 2013; Signer et al., 2014).Complete
blood cell count analysis was performed on peripheral blood using theHemavet
950 with MULTI-TROL Mouse as an equilibration control (Drew Scientific).
Western Blot Analysis
Mouse tissues were lysed in radio immunoprecipitation assay (RIPA) buffer
(Cell Signaling Technology). Of total protein, 100 mg was electrophoresed on
6% SDS-PAGE gels and transferred to a polyvinylidene fluoride (PVDF) mem-
brane. Proteins were detected with anti-Brca1 antiserum (1:100; GH118, kind
gift of Dr. Jos Jonkers), mouse monoclonal anti-Hip1 (1:1,000; 1B11, T.S.R.
laboratory; Ames et al., 2013), and rabbit polyclonal anti-gH2AX (1:1,000,
Cell Signaling Technology). Blots were developed with Supersignal West
Pico chemiluminescence substrate (Pierce).
Statistical Analysis
Statistical significance was assessed using a two-tailed Student’s t test with
p values (*p < 0.05, **p < 0.01, and ***p < 0.001). A Fisher’s exact test (*p <
0.05) was used to asses statistical significance in Figures 1G and 1L–1O.
For Kaplan-Meier curves depicting survival analyses, a log-rank test was
used. All statistical analyses were performed using GraphPad Prism version
7.00 for Windows. All RNA-seq expression data and accession codes can
be found at GEO: GSE91390.
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